Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | CCKAR | P32238 | 3/20 | 0.49 |
| ▸ | CCKBR | P32239 | 3/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401320 | 1.00 | ADAM17 (0.58) | ADAM17L3MBTL1CTSSCTSKACE | |
| SCHEMBL10310207 | 1.00 | ADAM17 (0.58) | ADAM17L3MBTL1CTSSCTSKACE | |
| SCHEMBL22804050 | 1.00 | ADAM17 (0.58) | ADAM17L3MBTL1CTSSCTSKACE | |
| SCHEMBL29400491 | 1.00 | ADAM17 (0.58) | ADAM17L3MBTL1CTSSCTSKACE | |
| SCHEMBL29401255 | 0.91 | ADAM17 (0.58) | ADAM17L3MBTL1CTSSCTSKCCKAR | |
| SCHEMBL18002447 | 0.91 | CTSS (0.50) | ADAM17L3MBTL1CTSSCTSKACE | |
| SCHEMBL29401597 | 0.91 | ADAM17 (0.58) | ADAM17L3MBTL1CTSSCTSKCCKAR | |
| SCHEMBL21309886 | 0.90 | L3MBTL1 (0.57) | ADAM17L3MBTL1CTSSCTSKCCKAR | |
| SCHEMBL29169598 | 0.90 | L3MBTL1 (0.57) | ADAM17L3MBTL1CTSSCTSKCCKAR | |
| SCHEMBL22804106 | 0.90 | ADAM17 (0.53) | ADAM17L3MBTL1ACECCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | disclosed |
| US-20090305995-A1 | AGONISTS AND ANTAGONISTS OF THE SOMATOSTATIN RECEPTOR | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| CN-101094861-A | Agonists and antagonists of the somatostatin receptor | NOVARTIS AG (CH) | 2007-12-26 | — | — | CN | disclosed |
| EP-1814900-A1 | AGONISTS AND ANTAGONISTS OF THE SOMATOSTATIN RECEPTOR | Novartis AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006053700-A1 | AGONISTS AND ANTAGONISTS OF THE SOMATOSTATIN RECEPTOR | NOVARTIS AG (CH) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090305995-A1 | AGONISTS AND ANTAGONISTS OF THE SOMATOSTATIN RECEPTOR | SSTR4, SSTR3, SSTR5 | ADAM17 812/4885L3MBTL1 1870/4885CTSS 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.